BAUSSS biomarker improves melanoma survival risk assessment

Anthony J. Dixon,Howard K. Steinman,Alexander Nirenberg,Christos C. Zouboulis,Michael Sladden,Catalin Popescu,Stuart Anderson,Caterina Longo,J. Meirion Thomas
DOI: https://doi.org/10.1111/jdv.20292
2024-09-03
Journal of the European Academy of Dermatology and Venereology
Abstract:The range of mortality risk within individual AJCC staging brackets is very wide. Administering adjuvant drug therapy based solely on AJCC T3b, T4a and T4b staging will result in many high‐risk patients over 60 years of age being denied such drugs while other patients under young patients will be offered drug therapy despite having a relatively low risk primary tumour. Background The American Joint Committee on Cancer (AJCC) method of staging melanoma is dated and inaccurate. It ignores important prognostic melanoma features, especially the patient's age. BAUSSS is more accurate in determining survival risk for primary cutaneous melanoma patients who have no clinical or imaging evidence of nodal or distant metastases. BAUSSS is an algorithm incorporating analysis of Breslow thickness, Age, Ulceration, Subtype of melanoma, Sex and Site. These are the six features from the patient history along with the details from the melanoma pathology report that are most predictive of mortality outcome. Objective To develop a single‐page document that allows the clinician to determine BAUSSS biomarker‐predicted prognosis in consultation with the patient. Method From various data sources, we developed an algorithm to predict melanoma mortality using the BAUSSS biomarker system. The single‐page algorithm was made available to download at https://globalmelanoma.net/bausss‐survival‐chart, thus being readily available without charge to all clinicians and their patients. Results BAUSSS method of determining melanoma prognosis is more accurate and less costly than the AJCC staging system. The only surgery the patient requires is wide local excision of the primary tumour. This method of ascertaining melanoma risk does not require added surgery, costs, hospitalization, tests and anaesthesia, such as would be required if sentinel lymph node biopsy was undertaken. BAUSSS can be a useful tool in determining which primary melanoma patients are at sufficiently high risk to be considered for adjuvant drug therapy. Conclusion We encourage clinicians to download and print in colour this single‐page BAUSSS mortality prediction tool, laminate it, and use it face to face with the patient in consultations. Not only will the patient be able to recognize his/her long‐term prognosis but will also be able to see how their tumour severity compares with others.
dermatology
What problem does this paper attempt to address?